Identification of the immune subtype of ovarian cancer patients by integrated analyses of transcriptome and single-cell sequencing data

[1]  A. Mes-Masson,et al.  Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes , 2022, Cancers.

[2]  W. Park,et al.  Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer , 2021, Cancer discovery.

[3]  Bo Li,et al.  Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer , 2021, EMBO molecular medicine.

[4]  M. Gilardi,et al.  B cells secrete GABA, which provokes a pro-tumor immune microenvironment. , 2021, Cancer cell.

[5]  Howard Y. Chang,et al.  Toward a better understanding of T cells in cancer. , 2021, Cancer cell.

[6]  S. Berger,et al.  An NK-like CAR T cell transition in CAR T cell dysfunction , 2021, Cell.

[7]  A. Jimeno,et al.  First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Yan Gao,et al.  Single-cell RNA-seq highlights a specific carcinoembryonic cluster in ovarian cancer , 2021, Cell death & disease.

[9]  K. Tsuneyama,et al.  Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages , 2021, Cancer Research.

[10]  A. Oza,et al.  Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[11]  Jason D. Wright,et al.  Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. , 2021, JAMA oncology.

[12]  J. Wolchok,et al.  Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways , 2021, Nature Reviews Clinical Oncology.

[13]  M. Baek,et al.  M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. , 2021, Biomaterials.

[14]  G. Curigliano,et al.  Therapeutic cancer vaccines revamping: technology advancements and pitfalls , 2021, Annals of Oncology.

[15]  P. Gimotty,et al.  Activating a collaborative innate-adaptive immune response to control metastasis. , 2021, Cancer cell.

[16]  Zhentao Yang,et al.  Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. , 2021, Cancer cell.

[17]  E. Jaffee,et al.  From bench to bedside: single-cell analysis for cancer immunotherapy. , 2021, Cancer cell.

[18]  D. Lambrechts,et al.  High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification , 2021, Genome Medicine.

[19]  R. Montironi,et al.  Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[20]  R. Bourgon,et al.  Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. , 2021, Cancer cell.

[21]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[22]  Jingjing Ding,et al.  Self‐Activatable Photo‐Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy , 2021, Advanced materials.

[23]  Weili Zhao,et al.  CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis , 2021, Signal Transduction and Targeted Therapy.

[24]  J. Si,et al.  Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization , 2021, Gut microbes.

[25]  Minoru Kanehisa,et al.  KEGG: integrating viruses and cellular organisms , 2020, Nucleic Acids Res..

[26]  F. Hodi,et al.  Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study , 2020, Clinical Cancer Research.

[27]  Lihua Zhang,et al.  Inference and analysis of cell-cell communication using CellChat , 2020, Nature Communications.

[28]  C. Madeddu,et al.  Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients , 2020, Scientific Reports.

[29]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[30]  S. Ansell,et al.  The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma. , 2019, Blood.

[31]  H. Cao,et al.  Lipotoxic Hepatocyte-Derived Exosomal miR-192-5p Activates Macrophages via Rictor/Akt/FoxO1 Signaling in NAFLD. , 2019, Hepatology.

[32]  Cesar M. Castro,et al.  Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. , 2019, JAMA oncology.

[33]  E. Swisher,et al.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. , 2019, JAMA oncology.

[34]  A. Oza,et al.  Epithelial ovarian cancer: Evolution of management in the era of precision medicine , 2019, CA: a cancer journal for clinicians.

[35]  D. Provencher,et al.  Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  C. Zahnow,et al.  DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer. , 2019, Cancer research.

[37]  D. Timmerman,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Daniel C. Scotto,et al.  Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma , 2019, Oncoimmunology.

[39]  A. Oza,et al.  Epithelial ovarian cancer , 2019, The Lancet.

[40]  Cuifeng Wang,et al.  Tunneling Nanotubular Expressways for Ultrafast and Accurate M1 Macrophage Delivery of Anticancer Drugs to Metastatic Ovarian Carcinoma. , 2019, ACS nano.

[41]  C. A. Speck-Hernandez,et al.  Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. , 2018, Cancer research.

[42]  L. Waldron,et al.  Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array , 2015, Clinical Cancer Research.

[43]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[44]  A. Regev,et al.  Spatial reconstruction of single-cell gene expression , 2015, Nature Biotechnology.

[45]  E. Goode,et al.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.

[46]  Georg Heinze,et al.  Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium , 2012, Cancer science.

[47]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[48]  Peter Langfelder,et al.  Fast R Functions for Robust Correlations and Hierarchical Clustering. , 2012, Journal of statistical software.

[49]  H. Hollema,et al.  Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.

[50]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[51]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..